Federal healthcare fraud enforcement is intensifying as authorities target drug marketing practices that can influence prescribing decisions. Takeda Pharmaceuticals, U.S.A. Inc. has agreed to pay $13,670,921 to resolve allegations that improper payments to physicians led to false claims being submitted to Medicare and other federal health care programs for antidepressant Trintellix.
As reported by the U.S. Department of Justice, the settlement resolves allegations that Takeda knowingly caused false claims by paying healthcare providers kickbacks to induce prescriptions of Trintellix, a treatment for major depressive disorder.
The government alleges that, from January 2014 to October 2020, Takeda provided improper remuneration including speaker honoraria and meals at high-end restaurants to healthcare professionals in violation of the Anti-Kickback Statute. Authorities contend the company placed certain providers in its...
A senior Iranian official has slammed the United Arab Emirates for being an aggressor, not merely a supporter of aggression, stating that the UAE cannot hide its aggressive nature and role behind ...